All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Targovax Announces Completed Enrollment in the ONCOS-102

Contact the Supplier

Lead Product(s): ONCOS-102,Pembrolizumab,Cyclophosphamide

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma who have had disease progression on treatment with anti-PD1 CPI.